Absence of Transmitted Resistance to HIV Integrase Inhibitors in Swiss Cohort

Data from the Swiss HIV Cohort Study showed no cases of transmitted resistance, in stark contrast to previous findings with other classes of antiretroviral therapy.

HIV strand transfer inhibitors (INSTIs) have become increasingly popular options for the initiation of antiretroviral therapy (ART). To analyze the prevalence of transmitted INSTI resistance, researchers conducted the Swiss HIV Cohort Study (SHCS) between 2008 (at INSTI introduction in Switzerland) and 2014, with minor pharmaceutical support. The highly representative cohort for HIV infection in Switzerland includes 85% of newly HIV-infected people and at least 75% of all patients on ART. The authors examined the presence of IAS-USA major and minor INSTI mutations among 1316 patients with ≥1 HIV integrase genotype done before INSTI exposure.

A major mutation (T66I) was present in only one specimen (0.1%); 38 samples (2.9%) had minor mutation…

Reviewing Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Absence of Transmitted Resistance to HIV Integrase Inhibitors in Swiss Cohort

Topics

Reviewing Author